TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07207954: A Phase 1a/1b, Randomized, Double-Blind, Placebo- and Active-Controlled, Single and Multiple Ascending Dose Study Evaluating the Comparative Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LFD-200 in Adult

Sponsor: Lifordi Immunotherapeutics, Inc. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 176 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$680,340

Rescue Site Savings

+$445,740

Unlock Full NCT07207954 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07207954 Rescue Dossier →